Digital AI in clinical trials: Building better trials before they st... With AI, trial sponsors are now reducing risk, accelerating timelines, and driving innovation by modelling what is most likely to work in the future.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.